These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25198405)

  • 1. Virologic and genetic evaluation of vemurafenib-induced skin cancers.
    Dika E; Patrizi A; Altimari A; Fiorentino M; La Placa M; Gruppioni E; Venturoli S; Vaccari S; Melotti B; Piraccini BM; Fanti PA
    Cutan Ocul Toxicol; 2015; 34(3):251-3. PubMed ID: 25198405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous adverse events during vemurafenib therapy.
    Chandrakumar SF; Yeung J
    J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eruptive squamous cell carcinomas after vemurafenib therapy.
    Mays R; Curry J; Kim K; Tsai K; Arora A; Khan F; Ramirez-Fort M; Ciurea A
    J Cutan Med Surg; 2013; 17(6):419-22. PubMed ID: 24138980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
    Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model for cutaneous squamous cell carcinoma in vemurafenib therapy.
    Kent R; Glorioso S; Nordberg ML
    J La State Med Soc; 2012; 164(6):311-3. PubMed ID: 23431672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil.
    Sinha R; Larkin J; Fearfield L
    Br J Dermatol; 2015 Apr; 172(4):1135-6. PubMed ID: 25234953
    [No Abstract]   [Full Text] [Related]  

  • 8. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.
    Holderfield M; Lorenzana E; Weisburd B; Lomovasky L; Boussemart L; Lacroix L; Tomasic G; Favre M; Vagner S; Robert C; Ghoddusi M; Daniel D; Pryer N; McCormick F; Stuart D
    Cancer Res; 2014 Apr; 74(8):2238-45. PubMed ID: 24523442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
    Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
    Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus evaluation of vemurafenib-induced skin epithelial tumors: a case series.
    Dika E; Patrizi A; Venturoli S; Fanti PA; Barbieri D; Strammiello R; Melotti B; La Placa M
    Br J Dermatol; 2015 Feb; 172(2):540-2. PubMed ID: 25041062
    [No Abstract]   [Full Text] [Related]  

  • 11. Vemurafenib-related cutaneous side effects ameliorated by acitretin.
    Chon SY; Sambrano BL; Geddes ER
    J Drugs Dermatol; 2014 May; 13(5):586-8. PubMed ID: 24809883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.
    Cassius C; Pages C; Roux J; Lhote R; Lavocat R; Réa D; Bagot M; Mourah S; Battistella M; Lebbé C; Dumaz N
    J Invest Dermatol; 2016 Jun; 136(6):1302-1305. PubMed ID: 26854489
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug safety evaluation of vemurafenib in the treatment of melanoma.
    Tsai KY; Nowroozi S; Kim KB
    Expert Opin Drug Saf; 2013 Sep; 12(5):767-75. PubMed ID: 23800008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
    Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
    Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib-induced neutrophilic panniculitis.
    Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
    Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients.
    Herms F; Kramkimel N; Regnier-Rosencher E; Carlotti A; Chanal J; Boitier F; Aractingi S; Dupin N; Avril MF
    Melanoma Res; 2016 Oct; 26(5):487-91. PubMed ID: 27261949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitiligo of the Face in a Patient Treated With Vemurafenib for Metastatic Melanoma.
    Nasca MR; Lacarrubba F; Ferraù F; Micali G
    J Drugs Dermatol; 2016 Jun; 15(6):766-8. PubMed ID: 27272087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vemurafenib-induced toxic epidermal necrolysis].
    Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
    Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-FDG PET/CT imaging of squamous cell carcinoma induced by Vemurafenib.
    Nguyen BD
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):64-6. PubMed ID: 26251366
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.